Cancer Biology · global
How Do Cancer Mutations Reshape DNA Folding? Study Finds a Common Pathway After BAF Loss of Function
When the BAF complex loses function, the genome does not simply become harder to read. A Nature study found that some regions instead allow more CTCF protein to bind, redrawing the spatial boundaries of gene regulation. Mouse experiments offer clues for intervention, but key questions remain before this could lead to treatment.
Changes in cancer are written not only in the DNA sequence but also in how DNA folds and which genes can come into contact with regulatory signals. Genes encoding components of the BAF chromatin remodeling complex frequently carry loss-of-function mutations in many cancers. Now, a study has identified a common response across cell and tissue models: when BAF loses function, binding by CTCF, a protein that defines spatial boundaries in the genome, increases, altering gene activity in turn.
The study, conducted by researchers at Weill Cornell Medicine and collaborators and published in Nature on October 28, combined pharmacological inhibition with ARID1A gene knockout experiments to trace the changes following impaired BAF function. Loss of ARID1A alone was sufficient to make chromatin at CTCF binding sites more accessible, pointing to a key role for the canonical BAF complex, or cBAF, within the BAF family.
BAF normally moves or removes the nucleosomes around which DNA is wrapped, helping regulate how readily genes can be read. It is therefore counterintuitive that some sites become more open after BAF loss. The researchers found that these regions not only gained more CTCF but also showed increases in components of the cohesin complex, which helps form DNA loops. This suggests a counterbalancing relationship between cBAF and this spatial organization machinery.
This imbalance further altered the genome’s three-dimensional arrangement. Boundaries of existing chromatin domains became stronger, and larger domains were subdivided into smaller, mutually insulated structures. Some longer-range contacts connecting enhancers and gene promoters were replaced by short loops near promoters. In other words, the changes affected not only whether DNA was accessible but also whether regulatory elements could reach the genes they originally contacted.
Another clue came from within the BAF family. The team found that CTCF can interact directly with the intact PBAF complex; when cBAF was reduced, PBAF accumulated at sites where CTCF binding increased. The institution’s announcement also noted that ISWI, another class of chromatin remodeling complexes, helps support CTCF activity. These findings extend the focus from a single impaired protein to the protein network that takes over after the balance is disrupted.
Mouse experiments provided further functional evidence: after Arid1a was knocked out, a population of highly proliferative cells expanded. Additional knockout of Ctcf, or of Pbrm1, which encodes a component of PBAF, reversed this change. This supports the involvement of CTCF and PBAF in abnormal proliferation in this model, but it does not amount to proof that existing tumors can be made to regress.
The study therefore proposes CTCF, PBAF, and ISWI as candidate avenues for future therapeutic research. Current evidence remains primarily based on cell and animal models, and an effective therapy targeting this mechanism has yet to be established. How to intervene selectively with drugs, whether the gene regulation needed by normal cells can be preserved, and which BAF-mutant tumors truly depend on this pathway will all determine whether this mechanistic discovery can advance into clinical use.